TH124135A - - Google Patents
Info
- Publication number
- TH124135A TH124135A TH801005666A TH0801005666A TH124135A TH 124135 A TH124135 A TH 124135A TH 801005666 A TH801005666 A TH 801005666A TH 0801005666 A TH0801005666 A TH 0801005666A TH 124135 A TH124135 A TH 124135A
- Authority
- TH
- Thailand
- Prior art keywords
- estradiol
- lactose
- levonorgestrel
- pharmaceuticals
- beta
- Prior art date
Links
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract 4
- 239000008101 lactose Substances 0.000 claims abstract 4
- 239000003814 drug Substances 0.000 claims abstract 3
- 239000000654 additive Substances 0.000 claims abstract 2
- 229940079593 drug Drugs 0.000 claims abstract 2
- 239000005426 pharmaceutical component Substances 0.000 claims 3
- 239000001913 cellulose Substances 0.000 claims 2
- 229920002678 cellulose Polymers 0.000 claims 2
- 108010010803 Gelatin Proteins 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 239000000470 constituent Substances 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 239000008273 gelatin Substances 0.000 claims 1
- 229920000159 gelatin Polymers 0.000 claims 1
- 235000019322 gelatine Nutrition 0.000 claims 1
- 235000011852 gelatine desserts Nutrition 0.000 claims 1
- 235000011837 pasties Nutrition 0.000 claims 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 abstract 4
- 229960005309 estradiol Drugs 0.000 abstract 3
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 abstract 2
- QMBJSIBWORFWQT-DFXBJWIESA-N Chlormadinone acetate Chemical compound C1=C(Cl)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 QMBJSIBWORFWQT-DFXBJWIESA-N 0.000 abstract 2
- 201000010538 Lactose Intolerance Diseases 0.000 abstract 2
- 229960001616 chlormadinone acetate Drugs 0.000 abstract 2
- 239000000262 estrogen Substances 0.000 abstract 2
- 229940011871 estrogen Drugs 0.000 abstract 2
- 229960004400 levonorgestrel Drugs 0.000 abstract 2
- 230000007774 longterm Effects 0.000 abstract 2
- 239000006187 pill Substances 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- XHJMDTAEPZXEKG-SLHNCBLASA-N (8r,9s,13s,14s,17r)-17-ethenyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C=C)[C@@H]4[C@@H]3CCC2=C1 XHJMDTAEPZXEKG-SLHNCBLASA-N 0.000 abstract 1
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 abstract 1
- RSEPBGGWRJCQGY-RBRWEJTLSA-N Estradiol valerate Chemical compound C1CC2=CC(O)=CC=C2[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCC)[C@@]1(C)CC2 RSEPBGGWRJCQGY-RBRWEJTLSA-N 0.000 abstract 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 abstract 1
- FQZLTMNDOCEKNR-JVRACWEPSA-N [C@@H]12C(CC(O)[C@@]1(C)CC[C@@H]1C3=C(CC[C@@H]21)C=C(O)C=C3)CCCCC(=O)OC3=CC2=C([C@H]1CC[C@@]4(C(CC[C@H]4[C@@H]1CC2)OC(CCCC)=O)C)C=C3 Chemical compound [C@@H]12C(CC(O)[C@@]1(C)CC[C@@H]1C3=C(CC[C@@H]21)C=C(O)C=C3)CCCCC(=O)OC3=CC2=C([C@H]1CC[C@@]4(C(CC[C@H]4[C@@H]1CC2)OC(CCCC)=O)C)C=C3 FQZLTMNDOCEKNR-JVRACWEPSA-N 0.000 abstract 1
- 229960003309 dienogest Drugs 0.000 abstract 1
- AZFLJNIPTRTECV-FUMNGEBKSA-N dienogest Chemical compound C1CC(=O)C=C2CC[C@@H]([C@H]3[C@@](C)([C@](CC3)(O)CC#N)CC3)C3=C21 AZFLJNIPTRTECV-FUMNGEBKSA-N 0.000 abstract 1
- 150000002009 diols Chemical class 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 229930182833 estradiol Natural products 0.000 abstract 1
- 229960004766 estradiol valerate Drugs 0.000 abstract 1
- 229960002568 ethinylestradiol Drugs 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 239000000583 progesterone congener Substances 0.000 abstract 1
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TH124135A true TH124135A (https=) | 2013-05-31 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Schindler | The “newer” progestogens and postmenopausal hormone therapy (HRT) | |
| Junge et al. | Metabolic and haemostatic effects of estradiol valerate/dienogest, a novel oral contraceptive: a randomized, open-label, single-centre study | |
| Africander et al. | Molecular mechanisms of steroid receptor-mediated actions by synthetic progestins used in HRT and contraception | |
| Sitruk-Ware | Hormonal contraception and thrombosis | |
| JP2019163318A5 (https=) | ||
| US8349820B2 (en) | Use of estradiol valerate or 17β-estradiol in combination with dienogest for oral therapy to maintain and/or increase feminine libido | |
| Sweeney et al. | Molecular modulation of estrogen-induced apoptosis by synthetic progestins in hormone replacement therapy: an insight into the women's health initiative study | |
| AR082998A1 (es) | Asociacion farmaceutica para tratar y/o prevenir mioma y/o endometriosis, uso de resveratrol y progestogeno, composicion farmaceutica para tratamiento y/o prevencion de mioma y/o endometriosis, medicamento para tratamiento y/o prevencion de mioma y/o endometriosis, kit y metodo para tratamiento y/o prevencion de mioma y/o endometriosis | |
| ATE493132T1 (de) | Arzneimittel umfassend wenigstens ein gestagen | |
| KR970069031A (ko) | 당 제피로부터 스테로이드의 방출이 조절되는 약제학적 정제 | |
| PE20080273A1 (es) | Composicion farmaceutica que contiene un progestageno, un estrogeno y un acido tetrahidrofolico | |
| JP2010508275A5 (https=) | ||
| Grandi et al. | Pharmacokinetic evaluation of desogestrel as a female contraceptive | |
| NO20022292L (no) | Nye topiske östrogenprogestogenpreparater med systemisk effekt | |
| Raps et al. | Resistance to APC and SHBG levels during use of a four-phasic oral contraceptive containing dienogest and estradiol valerate: a randomized controlled trial | |
| RU2007148080A (ru) | Составы и способы для лечения симптомов, связанных с циклом | |
| CA2608639A1 (en) | Pharmaceutical composition comprising progestogens and/or estrogens and 5-methyl-(6s)-tetrahydrofolate | |
| Guerra et al. | Progestins in combined contraceptives | |
| AU2003253506A1 (en) | Pharmaceutical composition comprising estetrol derivatives for use in cancer therapy | |
| WO2005077968A3 (en) | 17-methylene-or 17 - spiro - cyclopropane 7 - substituted estra - 1, 3, 5 (10) - triene derivatives with anti - estrogenic activity | |
| JP2008515909A5 (https=) | ||
| TH124135A (https=) | ||
| Bitzer et al. | Endometrial safety of an oral contraceptive containing estradiol valerate and dienogest | |
| Bouchard | Chlormadinone acetate (CMA) in oral contraception–a new opportunity | |
| Gandhi et al. | Evolution of Oral Contraceptive Pills: AB Gandhi and PA Supe |